ENDRA Life Sciences- Warrants (12/05/2022) Debt to Equity

The latest debt-to-equity ratio for NDRAW is 0.07. That is below the Technology sector average of 0.4. Investors often review this figure alongside ENDRA Life Sciences- Warrants (12/05/2022)'s historical trend and sector peers before judging valuation or financial health.

Against Technology companies, NDRAW currently prints 0.07 for debt-to-equity ratio, while the sector average sits near 0.4. That is roughly 83.1% below the sector mean. Large gaps often invite a closer look at ENDRA Life Sciences- Warrants (12/05/2022)'s growth, margins, and balance sheet.

A debt-to-equity ratio of 0.07 for ENDRA Life Sciences- Warrants (12/05/2022) is not 'good' or 'bad' on its own. Compare it with the peer average (0.4) and with NDRAW's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.

After noting NDRAW's debt-to-equity ratio (0.07), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack ENDRA Life Sciences- Warrants (12/05/2022)'s debt-to-equity ratio against similar Technology names. You can also browse sector and industry screens on Stockcircle for a broader set of Technology companies and their key multiples and fundamentals.